Kineta, Inc.

The momentum for this stock is not very good. Kineta, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Kineta, Inc..

News

Kineta (NASDAQ:KA) Trading 4.9% Higher

Zolmax Kineta, Inc. (NASDAQ:KA - Get Free Report) shares were up 4.9% during mid-day trading on Wednesday . The stock traded as high as $0.80 and last traded at $0.77. Approximately 157,595 shares changed...\n more…

Kintara Therapeutics: Clinical Trial Resumes Amid Merger Uncertainties

TipRanks Financial Blog Kintara Therapeutics (KTRA) has provided an update. Kintara Therapeutics and TuHURA Biosciences announced that Kineta, Inc. has resumed enrollment for its VISTA-101...\n more…

Kintara announces Kineta reopens enrollment for VISTA-101 clinical trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Kineta reopens enrollment for VISTA-101 clinical trial of KVA12123

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Globe Newswire Effective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for enrollment in the clinical study 30 patients have been enrolled in the...\n more…

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

PR Newswire TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer TuHURA Biosciences...\n more…